skip to main content
Idioma:
Tipo de recurso Mostra resultados com: Mostra resultados com: Índice

Incidence and Mortality of COVID-19-Associated Invasive Fungal Infections Among Critically Ill Intubated Patients: A Multicenter Retrospective Cohort Analysis

Zuniga-Moya, Julio C ; Papadopoulos, Benjamin ; Mansoor, Armaghan-E-Rehman ; Mazi, Patrick B ; Rauseo, Adriana M ; Spec, Andrej

Open forum infectious diseases, 2024-04, Vol.11 (4), p.ofae108-ofae108 [Periódico revisado por pares]

US: Oxford University Press

Texto completo disponível

Citações Citado por
  • Título:
    Incidence and Mortality of COVID-19-Associated Invasive Fungal Infections Among Critically Ill Intubated Patients: A Multicenter Retrospective Cohort Analysis
  • Autor: Zuniga-Moya, Julio C ; Papadopoulos, Benjamin ; Mansoor, Armaghan-E-Rehman ; Mazi, Patrick B ; Rauseo, Adriana M ; Spec, Andrej
  • Assuntos: Analysis ; Antifungal agents ; Coronaviruses ; Editor's Choice ; Epidemiology and Disease Surveillance ; India ; Medical centers ; Medical research ; Medicine, Experimental ; Mortality ; Patient outcomes ; Severe acute respiratory syndrome
  • É parte de: Open forum infectious diseases, 2024-04, Vol.11 (4), p.ofae108-ofae108
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
    Potential conflicts of interest.  A.S. reports grants from Astellas Global Development Pharma, Inc., grants from Scynexis, grants from Cidara, and grants and personal fees from Mayne Pharma. P.M., A.R., B.P., A.E.M., and J.C.Z.M. do not have potential conflict of interests.
  • Descrição: Abstract Background An association between coronavirus disease 2019 (COVID-19)–associated invasive fungal infections (CAIFIs) and high mortality among intubated patients has been suggested in previous research. However, some of the current evidence was derived from small case series and multicenter studies conducted during different waves of the COVID-19 pandemic. We examined the incidence of CAIFIs and their associated mortality using a large, multicenter COVID-19 database built throughout the pandemic. Methods We conducted a retrospective analysis of the National COVID Cohort Collaborative (N3C) database collected from 76 medical centers in the United States between January 2020 and August 2022. Patients were 18 years or older and intubated after severe acute respiratory syndrome coronavirus 2 infection. The primary outcomes were incidence and all-cause mortality at 90 days. To assess all-cause mortality, we fitted Cox proportional hazard models after adjusting for confounders via inverse probability weighting. Results Out of the 4 916 229 patients with COVID-19 diagnosed during the study period, 68 383 (1.4%) met our cohort definition. The overall incidence of CAIFI was 2.80% (n = 1934/68 383). Aspergillus (48.2%; n = 933/1934) and Candida (41.0%; n = 793/1934) were the most common causative organisms. The incidence of CAIFIs associated with Aspergillus among patients who underwent BAL was 6.2% (n = 83/1328). Following inverse probability weighting, CAIFIs caused by Aspergillus (hazard ratio [HR], 2.0; 95% CI, 1.8–2.2) and Candida (HR, 1.7; 95% CI, 1.5–1.9) were associated with increased all-cause mortality. Systemic antifungals reduced mortality in 17% of patients with CAIFI with Aspergillus and 24% of patients with CAIFI with Candida. Conclusions The incidence of CAIFI was modest but associated with higher 90-day all-cause mortality among intubated patients. Systemic antifungals modified mortality.
  • Editor: US: Oxford University Press
  • Idioma: Inglês
Links
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.